## TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the of existing share attached:		•							
2 Reason for the notification (please tick the appropriate box or boxes):									
An acquisition or disposal of voting rights								Х	
An acquisition or disposal of qualifying financial acquisition of shares already issued to which was acquisition or disposal of instruments with a financial instruments					voting rights are attached				
An event changin		down of voti	ng rig	ıhts					
Other (please specify):									
3. Full name of person(s) subject to the notification obligation:				Abingworth LLP Abingworth Bioventures V LP Abingworth Bioequities Master Fund Limited					
4. Full name of shareholder(s) (if different from 3.):iv				Bank of New York (Nominees) Limited (as nominee for Abingworth Bioventures V LP)  Jefferies & Co Inc. (as nominee for Abingworth Bioequities Master Fund Limited)				nee for	
5. Date of the transaction and date on which the threshold is crossed or reached: <sup>V</sup>				23 May 2011					
6. Date on which issuer notified:				2 June 2011					
7. Threshold(s) that is/are crossed or reached: vi, vii			Above 5% - Abingworth Bioventures V LP Above 8% - Abingworth LLP						
8. Notified details: Abingworth Bioventures									
A: Voting rights attached to shares viii, ix									
Class/type of shares	to the triggering transaction			sulting situation after the triggering transaction					
if possible using the ISIN CODE				nares	Number of voting % of voting rights			rights * Indire	
	Jilaies	Rights	Dire	ct	Direct xi	Indirect xii	Direct	ct	

B: Qualifying Financial Instruments							
Resulting situation after the triggering transaction							
Type of financial instrument	Expiration date xiii	Exercise/ Conversion Period xiv	Number of voting rights that may be acquired if the instrument is exercised/ converted.	% of voting rights			

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi							
Resulting situation after the triggering transaction							
Type of financial instrument	Exercise price	Expiration date xvii	Exercise/ Conversion period xviii	Number of voting rights instrument refers to	% of voting rights xix, xx	J	
					Nominal	Delt a	

Total (A+B+C)									
Number of voting rights				Percentage of voting rights					
22,573,542				5.93%					
8. Notified detail	s: Abingwo	orth LLP							
A: Voting rights	A: Voting rights attached to shares viii, ix								
Class/type of shares	Situation previous to the triggering transaction		Resulting situation after the triggering transaction					on	
if possible using the ISIN CODE	Number of	Number of	Number of share		Number o	Number of voting rights		% of voting rights *	
	Shares	Voting Rights	Direct		Direct xi	Indirect xii	Direct	Indire ct	
Sinclair Pharma plc GB0033856740 1p Ords		12,880,794				33,433,227		8.78%	

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xvi, xvi  Resulting situation after the triggering transaction  Type of financial instrument    Exercise   Price   Expiration   Exercise   Conversion   Price   Expiration   Exercise   Conversion   Price   Expiration   Exercise   Sinstrument   Price   Price   Sinstrument   Exercise   Sinstrument   Exercise   Sinstrument   Sinstrume	Resulting situation	atter the t	triggering	transa	Ction				
Resulting situation after the triggering transaction  Type of financial instrument	Type of financial Expiration date xiii				right acqu instr	ts that may be uired if the rument is	% of voting rights		
Resulting situation after the triggering transaction  Type of financial instrument									
Type of financial instrument   Exercise   Expiration date   Exercise   Conversion period   Instrument refers to   Number of voting rights   % of voting rights   Number of voting rights   Nominal   Nominal   Nominal     Nominal     Nominal     Nominal     Nominal   Nomi			s with sir	milar e	economic e	fect to C	Qualifying Fina	ncial	
Instrument price date xvii Conversion period xviii instrument refers to rights xix, xx   Nominal   Nominal    Total (A+B+C)  Number of voting rights Percentage of voting rights   8.78%    9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi    Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.	Resulting situation	after the t	triggering	transa	ction				
Total (A+B+C)  Number of voting rights  33,433,227  8.78%  9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi  Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:		strument price date xvii Coi		Conversion			% of voting rights	% of voting rights xix, xx	
Number of voting rights  33,433,227  8.78%  9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ***  Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:								Nominal	Del a
Number of voting rights  33,433,227  8.78%  9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi  Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:									
Number of voting rights  33,433,227  8.78%  9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi  Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:									
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: **Xi    Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:									
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi  Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:									
Abingworth Bioventures V LP (which holds 22,573,542 shares in the company (5.93%)) and Abingworth Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:									
Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both manage Abingworth LLP.  Proxy Voting:							ung rignis and	or the	
	Bioequities Master Fund Limited (which holds 10,859,685 shares in the company (2.85%)) are both managed by								
	Proxy Voting:								
To the proxy holder.	, ,	proxy ho	older:						
		P. 0// III							

12. Date on which proxy holder will cease to hold voting rights:
--

13. Additional information:	
14. Contact name:	John Heard
15. Contact telephone number:	0207 534 1508